Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Sarcomatoid Renal Cell Carcinoma
  2. Cabozantinib After an Immune Checkpoint Inhibitor in mRCC
  3. Safety and Efficacy of Nivolumab in Advanced ccRCC
  4. Improved Efficacy WIth Nivolumab Plus Ipilimumab in Patients With Advanced RCC
  5. Immune Checkpoint Inhibitors for Papillary Renal Cell Carcinoma
  6. Impact of COVID-19 Pandemic on Treatment Patterns in Metastatic Clear Cell Renal Cell Carcinoma
  7. Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Untreated Metastatic RCC and Sarcomatoid Features
  8. Toxicities, Body Composition, and hrQoL Among Long-Term Survivors Treated With Antibodies to PD-1 and PD-L1
  9. Prognostic Models of Survival Following Cytoreductive Nephrectomy
  10. Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic RCC

Elsewhere

Recently Updated